Abstract:Abstract Background A growing body of evidence suggests that epithelial cell-derived microRNAs are involved in the pathogenesis of inflammatory bowel disease (IBD). This immunological impairment leads to altered colonic epithelial permeability and the release of inflammatory cytokines, such as IL-33. In this prospective cohort study, we studied the expression of epithelial cell-derived microRNAs (miRNA) in Crohn’s disease (CD) patients compared to healthy controls. We also investigated their potential role in regulating inflammation in experimental IBD animal models. Methods We prospectively collected terminal ileum tissue samples via ileocolonoscopy from non-IBD healthy control (n=26), CD patients in remission (n=34) and active CD patients (n=42). CD remission was defined as clinical remission with a Crohn’s disease activity index score of less than 150 and the achievement of endoscopic mucosal healing. Both inflamed and non-inflamed lesions were sampled in the active CD patients. miRNA levels were measured by small-RNA sequencing and also validated via qRT-PCR. Diagnostic abilities of specific miRNAs found were evaluated by receiver operating characteristic (ROC) curve analysis. A signature of miRNAs was selected from RNA sequencing and qRT-PCR and single-strand mimics of these miRNAs were delivered in the 2.5% dextran sodium sulfate colitis model to determine the effect. Histologic grading and immunohistochemistry evaluation and flow cytometry analyses were performed. Results From the prospective study cohort of CD and non-IBD healthy control (mean follow-up period of 13.06 months), we found a distinct array of miRNAs between groups. Small-RNA sequencing of CD patients in remission and active state (both in inflamed and non-inflamed tissue) revealed distinct microRNA profiles. Through qRT-PCR validation, we found that the expression levels of miR-141-3p, miR-338-3p, miR-378a-3p, and miR-200b-3p were significantly decreased, while miR-125b-5p, miR-29b-3p and miR-155-5p were significantly increased in the inflamed tissue of active CD patients. ROC curve analysis of these miRNAs suggested that they have varying diagnostic activities related to both clinical disease activity and endoscopic inflammation status. In an IBD animal model, the delivery of miR-338-3p and miR-378-3p demonstrated an anti-inflammatory effect, as evidenced both histologically and in immunohistochemistry data, as well as in flow cytometry analyses. Consistent results were observed when these two miRNAs were combined. Conclusion We report miR-338-3p and miR-378a-3p as distinct features in mucosa of CD patients and these data support the promising future of use of these miRNAs as potential therapeutic targets for novel IBD therapies.

Association of Reduced Heme Oxygenase-1 with Decreased Microrna-196a2 Expression in Peripheral Blood Mononuclear Cells of Patients with Intestinal Behcet'S Disease

Alterations in microRNA expression profiles in inflamed and noninflamed ascending colon mucosae of patients with active Crohn's disease

P913 Interactions between Intestinal Microbiota and micro-RNAs in Inflammatory Bowel Disease

Relative abundance of Megamonas hypermegale and Butyrivibrio species decreased in the intestine and its possible association with the T cell aberration by metabolite alteration in patients with Behcet’s disease (210 characters)

Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights

P002 Regulation of miR-338-3p and miR-378a-3p in the intestinal mucosa of Crohn’s disease: Potential targets for modulating inflammation

P1230 Integrated analysis of microbiome and metabolome reveals disease-specific profiles in inflammatory bowel disease and intestinal Behcet’s disease

Integrated Analysis of Microbiome and Metabolome Reveals Disease-Specific Profiles in Inflammatory Bowel Diseases and Intestinal Behçet's Disease

Altered Microrna Expression in Inflamed and Non-Inflamed Terminal Ileal Mucosa of Adult Patients with Active Crohn'S Disease

microRNA–mRNA Networks Linked to Inflammation and Immune System Regulation in Inflammatory Bowel Disease

Clinical Significance of microRNA-146a in Patients with Ulcerative Colitis

miRNA-133a-UCP2 pathway regulates inflammatory bowel disease progress by influencing inflammation, oxidative stress and energy metabolism.

The Expression of HBD-2, NF-kB, IL-6 and IL-23 in Colonic Mucosa of Ulcerative Colitis and Irritable Bowel Syndrome

Investigation of key miRNAs and their target genes in inflammatory bowel diseases and colitis-associated colorectal cancers using miRNA proifling and bioinformatic tools

P132 Overexpression of miR-376a-3p in exosomes circulating in peripheral blood of patients with Crohn's disease

Mir-19B Downregulates Intestinal SOCS3 to Reduce Intestinal Inflammation in Crohn’s Disease

MiR-200b in heme oxygenase-1-modified bone marrow mesenchymal stem cell-derived exosomes alleviates inflammatory injury of intestinal epithelial cells by targeting high mobility group box 3

Aberrant monocyte subsets in patients with Behçet's disease

Investigating the association between the tissue expression of miRNA‐101, JAK2/STAT3 with TNF‐α, IL‐6, IL‐1β, and IL‐10 cytokines in the ulcerative colitis patients

High Intestinal and Systemic Levels of Interleukin-23/T-Helper 17 Pathway in Chinese Patients with Inflammatory Bowel Disease

GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Behçet’s disease